Company Directory / research

PrivateFor profitresearchSouth Korea
Cyrus Therapeutics is a biotechnology company that discovers and develops molecule medicines to conquer chronic diseases.
Size
11-50 people: larger than 33% of companies with a size listed
Age
7 years old.
Reach
No web traffic ranking listed.
BiotechnologyClinical TrialsMedicalPharmaceutical
Funding, as listed
$39B currency not stated
What the source datasets report. We have not watched these rounds ourselves.
Everything the source datasets list about Cyrus Therapeutics, field by field. Contact details are held but never shown.
The company
Where
Size and reach
Funding, as listed
About this record
Growth, as the source summarises it
Cyrus Therapeutics may be growing as it has secured a significant payment of ₩208 billion for its SOS1 inhibitor for cancer, indicating a substantial revenue influx from a licensing deal. This financial transaction suggests a successful monetization of the company's research and development efforts in the biotechnology and pharmaceutical industry. The deal with Yuhan also implies a level of confidence in Cyrus Therapeutics' product and its potential market value, which can be seen as a positive indicator of the company's business health and growth trajectory.
Summaries written by the source dataset, not by us, and not checked.
research in South Korea.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 13,309 companies in South Korea and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.